DXCM Stock Recent News
DXCM LATEST HEADLINES
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on behalf of long-term stockholders following a class action complaint that was filed against DexCom on August 21, 2024 with a Class Period from January 8, 2024 to July 25, 2024. Our investigation concerns whether the board of directors of DexCom have breached their fiduciary duties to the company.
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
DexCom, Inc. (NASDAQ:DXCM ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Jacob Steven Leach - President & COO Jereme M. Sylvain - Executive VP, CFO & Chief Accounting Officer Kevin Ronald Sayer - Executive Chairman & CEO Sean Christensen - Vice President of Finance and Investor Relations Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
Dexcom beat estimates for second-quarter results on Wednesday, driven by strong demand for its continuous glucose monitors, and named Jake Leach as its CEO.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan.
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.* Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for eithe.